Health TrialsbyHealthPanel

Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management

ConditionsPainCancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-70
SponsorTaipei Medical University Hospital

About this trial

Over half of cancer patients experience cancer-related pain. Despite advances in pain management with opioids, many patients continue to suffer from chronic cancer pain. The underlying mechanisms of cancer-related pain remain poorly understood, but they may be linked to brain neuroplasticity. As a result, some researchers suggest that targeting the motor cortex in cancer patients could improve pain management. However, few studies have investigated the effectiveness of remodeling neuroplasticity with repetitive transcranial magnetic stimulation (rTMS) to reduce cancer-related pain. To validate the use of rTMS in cancer-related pain, we plan to conduct a randomized controlled trial involving 30 cancer pain patients. Participants will be randomly assigned to receive either rTMS or sham rTMS treatment. Functional magnetic resonance imaging (fMRI) and pain index assessments will be conducted before and after the treatment to evaluate the outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients have cancer pain symptoms, confirmed by a physician as cancer pain or neuropathic cancer pain

Experienced the worst pain NRS score ≥ 4

The patient demonstrate good cognition and is able to cooperate with the assessment of pain severity.

The estimated survival time exceeds 3 months.

Disqualifiers

Individuals who have undergone head surgery or have metal implants in the head.

Individuals with implanted cardiac pacemakers or cochlear prostheses.

Have a history of epilepsy.

Patients diagnosed with primary brain tumors or metastatic brain lesions.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Repetitive transcranial magnetic stimulation (rTMS)

    Device

    Repetitive transcranial magnetic stimulation toward for cancer pain (real and sham control)

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Repetitive transcranial magnetic stimulationExperimental treatment 1 intervention
Group B: Sham Repetitive transcranial magnetic stimulationSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Brief Pain Inventory, BPI

BPI is to assess the severity of pain and the impact of pain on daily functions, including Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.

Time frame
Assess the BPI outcome before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.
2

McGill Pain Questionnaire

The McGill Pain Questionnaire (MPQ) is a self-report measure used by patients with various diagnoses to assess pain. It consists of 78 words, from which respondents select those that best describe their pain experience. The words are categorized as follows: Dimensions 1 to 10 (pain descriptors): 3 words Dimensions 11 to 15 (affective components of pain): 3 words Dimension 16 (evaluation of pain): 1 word Dimensions 17 to 20 (miscellaneous): 1 word. Scores are calculated by summing the values associated with each selected word, with scores ranging from 0 (no pain) to 78 (severe pain). Qualitative differences in pain are reflected in the respondent's word choices.

Time frame
Assess MPQ scores before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.

Secondary outcomes

1

Numerical Rating Scale, NRS

The Numeric Rating Scale (NRS) is commonly used to measure pain intensity and is well validated. It is scored from 0 to 10, with 0 representing no pain and 10 representing the worst pain imaginable

Time frame
Assess the NRS scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.
2

Visual Analogue Scale , VAS

The Visual Analog Scale (VAS) is a validated, subjective measure of both acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum from 'no pain' to 'worst pain.'

Time frame
Assess the VAS scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.
3

Resting-state functional imaging, rsfMRI

In fMRI, by adding each pixel, the time course of a pixel is related to the average time course of the corresponding region of interest (ROI). In this context, the cross-correlation coefficient map for each seed ROI will be generated. This cross-correlation coefficient map will then undergo Fisher's z-transformation to approximate a normal distribution.

Time frame
Assess the fMRI results before the intervention and after 2 weeks of interventions.
4

Beck Depression Inventory, BDI

BDI is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Each answer is being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms.

Time frame
Assess the BDI scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Taipei Medical University Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: